- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 2
The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of April 2, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 2.
Number 5: A recently published descriptive review finds a significant time lag between the approval of biosimilar infliximab and its acceptance in Irish hospitals.
Number 4: The Senate Homeland Security and Government Affairs Committee has released a report on prescription drug price increases that affect drugs that seniors use most. According to the report, drug prices rise at approximately 10 times the rate of inflation.
Number 3: CMS will lower the maximum co-payment amount for low-income subsidy beneficiaries for biosimilars.
Number 2: Samsung Bioepis and Biogen have reached a settlement with AbbVie that will allow the biosimilar adalimumab, Imraldi, to launch in Europe later this year.
Number 1: Celltrion has announced that the FDA has issued Complete Response Letters for 2 of its proposed biosimilar products.
Also this week, expert contributor Sonia T. Oskouei explains 9 key facts about biosimilar interchangeability in the United States.
Finally, last week, our e-newsletter asked whether you think one payer’s recent decision not to undertake a nonmedical switch to a biosimilar is good news for patients.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
